SRR598124
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.448
- INTERFERON_ALPHA_RESPONSE+0.417
- MYOGENESIS+0.406
- ESTROGEN_RESPONSE_LATE+0.373
- INFLAMMATORY_RESPONSE+0.368
- APICAL_SURFACE+0.357
- ANGIOGENESIS+0.349
- KRAS_SIGNALING_DN+0.348
- COAGULATION+0.345
- INTERFERON_GAMMA_RESPONSE+0.328
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.589
- MYC_TARGETS_V2-0.579
- MYC_TARGETS_V1-0.525
- DNA_REPAIR-0.473
- PROTEIN_SECRETION-0.432
- UNFOLDED_PROTEIN_RESPONSE-0.365
- E2F_TARGETS-0.350
- NOTCH_SIGNALING-0.311
- MTORC1_SIGNALING-0.309
- G2M_CHECKPOINT-0.284
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607538 | GTEX | — | 0.954 |
| 2 | SRR600724 | GTEX | — | 0.945 |
| 3 | SRR1499630 | GTEX | — | 0.942 |
| 4 | SRR1489971 | GTEX | — | 0.940 |
| 5 | SRR604366 | GTEX | — | 0.939 |
| 6 | SRR1334033 | GTEX | — | 0.939 |
| 7 | SRR1397906 | GTEX | — | 0.928 |
| 8 | ERR2598337 | fetal | fetal | 0.925 |
| 9 | SRR1082759 | GTEX | — | 0.924 |
| 10 | SRR598638 | GTEX | — | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.448 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.417 | Inavolisib | — uncovered |
| MYOGENESIS | 0.406 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.373 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.368 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.357 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.349 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.348 | Remibrutinib | — uncovered |
| COAGULATION | 0.345 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.328 | Idelalisib | — uncovered |
| COMPLEMENT | 0.324 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.318 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.302 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.298 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.243 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.218 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.206 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |